87 related articles for article (PubMed ID: 23588081)
1. Protein modelling of a novel KIT mutation (N567Y) in the gastrointestinal stromal tumour.
Alyuruk H; Calibasi G; Cavas L; Baskin Y; Oztop I; Ellidokuz H; Yilmaz U
Eur J Cancer; 2013 Jul; 49(10):2449-52. PubMed ID: 23588081
[No Abstract] [Full Text] [Related]
2. Imatinib-associated tumour response in a dog with a non-resectable gastrointestinal stromal tumour harbouring a c-kit exon 11 deletion mutation.
Kobayashi M; Kuroki S; Ito K; Yasuda A; Sawada H; Ono K; Washizu T; Bonkobara M
Vet J; 2013 Oct; 198(1):271-4. PubMed ID: 23820134
[TBL] [Abstract][Full Text] [Related]
3. Polyclonal resistance in gastrointestinal stromal tumor treated with sequential kinase inhibitors.
Loughrey MB; Waring PM; Dobrovic A; Demetri G; Kovalenko S; McArthur G
Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6205-6; author reply 6206-7. PubMed ID: 17062700
[No Abstract] [Full Text] [Related]
4. Acquired resistance to imatinib in gastrointestinal stromal tumours caused by multiple KIT mutations.
Wardelmann E; Thomas N; Merkelbach-Bruse S; Pauls K; Speidel N; Büttner R; Bihl H; Leutner CC; Heinicke T; Hohenberger P
Lancet Oncol; 2005 Apr; 6(4):249-51. PubMed ID: 15811621
[No Abstract] [Full Text] [Related]
5. Molecular approaches to resolve diagnostic dilemmas: the case of gastrointestinal stromal tumor and leiomyosarcoma.
Trent JC; Lazar AJ; Zhang W
Future Oncol; 2007 Dec; 3(6):629-37. PubMed ID: 18041915
[TBL] [Abstract][Full Text] [Related]
6. Pathological response of gastrointestinal stromal tumour to imatinib treatment correlates with tumour KIT mutational status in individual tumour clones.
Loughrey MB; Beshay V; Dobrovic A; Zalcberg J; Waring PM
Histopathology; 2006 Jul; 49(1):99-100. PubMed ID: 16842259
[No Abstract] [Full Text] [Related]
7. Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate.
Wardelmann E; Merkelbach-Bruse S; Pauls K; Thomas N; Schildhaus HU; Heinicke T; Speidel N; Pietsch T; Buettner R; Pink D; Reichardt P; Hohenberger P
Clin Cancer Res; 2006 Mar; 12(6):1743-9. PubMed ID: 16551858
[TBL] [Abstract][Full Text] [Related]
8. Gastrointestinal stromal tumors (GISTs): a pathology view point.
Sornmayura P
J Med Assoc Thai; 2009 Jan; 92(1):124-35. PubMed ID: 19260254
[TBL] [Abstract][Full Text] [Related]
9. KIT mutations and imatinib dose effects in patients with gastrointestinal stromal tumors.
De Giorgi U
J Clin Oncol; 2007 Mar; 25(9):1146-7; author reply 1147-8. PubMed ID: 17369583
[No Abstract] [Full Text] [Related]
10. Exploring the cause of drug resistance by the detrimental missense mutations in KIT receptor: computational approach.
Rajasekaran R; Sethumadhavan R
Amino Acids; 2010 Aug; 39(3):651-60. PubMed ID: 20140688
[TBL] [Abstract][Full Text] [Related]
11. [Study on the mechanism of imatinib-induced resistance in gastrointestinal stromal tumors].
Zhou Y; Hou YY; Tan YS; Lu SH; Hou J; Liu JL; Qin J; Shen KT; Sun YH
Zhonghua Zhong Liu Za Zhi; 2009 Aug; 31(8):597-601. PubMed ID: 20021947
[TBL] [Abstract][Full Text] [Related]
12. Current management of GIST.
Blanke C
Clin Adv Hematol Oncol; 2004 May; 2(5):280, 283. PubMed ID: 17682286
[No Abstract] [Full Text] [Related]
13. Double resistance to imatinib and AMG 706 caused by multiple acquired KIT exon 17 mutations in a gastrointestinal stromal tumour.
Grabellus F; Ebeling P; Worm K; Sheu SY; Antoch G; Frilling A; Schmid KW
Gut; 2007 Jul; 56(7):1025-6. PubMed ID: 17566038
[No Abstract] [Full Text] [Related]
14. Secondary C-kit mutation is a cause of acquired resistance to imatinib in gastrointestinal stromal tumor.
Zheng S; Pan YL; Tao DY; Wang JL; Huang KE
Scand J Gastroenterol; 2009; 44(6):760-3. PubMed ID: 19096980
[TBL] [Abstract][Full Text] [Related]
15. Is there a role for neoadjuvant treatment with Gleevec for large rectal gastrointestinal stromal tumors?
Wasserberg N; Nunoo-Mensah JW; Beart RW; Ker TS
Int J Colorectal Dis; 2007 Aug; 22(8):981-2. PubMed ID: 16583196
[No Abstract] [Full Text] [Related]
16. [A new genetic diagnosis of familiar gastrointestinal stromal tumour].
Wadt K; Andersen MK; Hansen TV; Gerdes AM
Ugeskr Laeger; 2012 May; 174(21):1462-4. PubMed ID: 22640790
[TBL] [Abstract][Full Text] [Related]
17. Aggressive gastrointestinal stromal tumour of the oesophagus with homozygous KIT exon 11 deletion mutation.
Cho J; Kang GH; Kim KM; Park J; Shim YM
Pathology; 2012 Apr; 44(3):260-1. PubMed ID: 22437744
[No Abstract] [Full Text] [Related]
18. [Effect of c-kit mutation on the prognosis of gastrointestinal stromal tumors: a meta-analysis].
Zhao WY; Cao H; Zhang Y; Shen ZY; Wu ZY
Zhonghua Wai Ke Za Zhi; 2009 Jun; 47(11):857-62. PubMed ID: 19961019
[TBL] [Abstract][Full Text] [Related]
19. KIT immunohistochemistry and mutation status in gastrointestinal stromal tumours (GISTs) evaluated for treatment with imatinib.
Loughrey MB; Trivett M; Beshay V; Dobrovic A; Kovalenko S; Murray W; Lade S; Turner H; McArthur GA; Zalcberg J; Waring PM
Histopathology; 2006 Jul; 49(1):52-65. PubMed ID: 16842246
[TBL] [Abstract][Full Text] [Related]
20. Gastric GI stromal tumors (GISTs): the role of surgery in the era of targeted therapy.
Heinrich MC; Corless CL
J Surg Oncol; 2005 Jun; 90(3):195-207; discussion 207. PubMed ID: 15895440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
